Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in von Hippel-Lindau disease
ChiCTR1800018640Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in von Hippel–Lindau disease (VHL), sponsored by Peking University First Hospital. Primary endpoints: Efficacy and Safety. Started Sep 2018; status: recruiting.
02
Drugs
axitinib
03
Conditions
von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on ChiCTR1800018640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018640.